{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 141 of 169', 'Infants and children: low systolic BP (age specific) or greater than 30% decrease in', 'systolic BP', 'Adults: systolic BP of less than 90 mm Hg or greater than 30% decrease from that', \"person's baseline\", 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 142 of 169', 'Appendix 7: Country-specific requirements', 'JAPAN', 'Section 6 Objectives and endpoints', 'In Japan, the maintenance endpoints of IGA 0/1 and EASI75 at Week 52 for subjects', 'achieving clinical response at Week 16 are evaluated as primary maintenance endpoints.', 'This regulatory requirement will have no impact on the analysis since an adjustment for', 'multiplicity is implemented for these 2 endpoints. Please see Section 12.3.4 for details on', 'the multiple testing procedure applied to control the overall type 1 error rate for the', 'trial.', 'Section 8.2 Inclusion criteria - Inclusion criterion no. 1', 'Written informed consent and any locally required authorisation obtained from the subject', 'prior to performing any protocol-related procedures, including screening evaluations.', 'In Japan, the legal representative must sign the informed consent if the subject is below', '20 years of age.', 'Section 8.2 Inclusion criteria - Inclusion criterion no. 2', 'Age 18 and above.', 'In Japan, inclusion criterion no. 2 will be as follows: Japanese subjects aged 18 and', 'above.', 'Section 9.9.3 Drug accountability', 'The investigator is fully responsible for the IMPs at the trial site and for maintaining adequate', 'control of the IMPs and for documenting all transactions with them.', 'In Japan, it is the Head of Institute who is responsible for the IMP at the trial site.', 'Used syringes will be destroyed at the trial site provided the trial site has procedures in place', 'for such IMP destruction.', 'Trial sites which do not have such IMP destruction procedures in place will dispose used', 'syringes in sharps bins which will be shipped to the contract manufacturing organisation', '(CMO).', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 143 of 169', 'In Japan, used syringes will be destroyed at the trial sites.', 'Section 9.11 Reporting product complaints', 'Any defects or issues with the IMP as well as any device deficiency (including malfunctions,', 'use errors, and inadequate labelling) must be reported to Global Pharmacovigilance, LEO on', 'the trial-specific (paper) Complaint Form within 3 days of first knowledge.', 'Critical complaints (defined as any issue, defect, or device deficiency that has or potentially', 'could have a serious impact for the subject [e.g., SAE or large particles in the syringe]) must', 'be reported to Global Pharmacovigilance, LEO within 24 hours.', 'In Japan, product complaints must be reported to Pharmacovigilance, LEO K.K. using', 'the contact information below:', 'Fax number: +81 3 4243 3311', 'E-mail address: clinical_trial_jp@leo-pharma.com', 'Note: reports sent to the above fax number and email address will automatically be', 'forwarded to Global Pharmacovigilance, LEO.', 'Section 10.1 Overview', 'Subjects participating in the trial will be under careful supervision of a dermatologist or', 'allergist. Investigators must be experienced in treating AD and have documented experience', 'and/or training in use of the assessments required by the protocol and must be either a', \"physician, certified physician's assistant, or advanced registered nurse practitioner.\", 'In Japan, investigators must be a dermatologist.', 'Section 11.3.1 Investigator reporting responsibilities', 'Any SAE must be reported to LEO on the (paper) SAE Form within 24 hours of first', 'knowledge. The completed SAE form must be faxed or scanned and e-mailed to Global', 'Pharmacovigilance, LEO.', 'In Japan, SAEs must be reported to Pharmacovigilance, LEO K.K. using the contact', 'information below:', 'Fax number: +81 3 4243 3311', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}